Trial Profile
A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 04 Jul 2012 Company added in the association field as reported by EudraCT.
- 15 Mar 2012 This trial is recruiting in Spain and France.
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.